Spots Global Cancer Trial Database for oropharyngeal
Every month we try and update this database with for oropharyngeal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | NCT03611205 | Oropharyngeal S... HPV Positive Or... | Computed Tomogr... Positron Emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Photon/Proton Radiation Therapy for Oropharyngeal Cancers | NCT00797446 | Oropharyngeal C... | 18 Years - | University of Florida | ||
| Photon/Proton Radiation Therapy for Oropharyngeal Cancers | NCT00797446 | Oropharyngeal C... | 18 Years - | University of Florida | ||
| Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation | NCT01958515 | Head and Neck C... HPV (Human Papi... Oropharyngeal | research blood ... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation | NCT01958515 | Head and Neck C... HPV (Human Papi... Oropharyngeal | research blood ... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma | NCT01855451 | HPV Positive Or... | Cetuximab RT (70 Gy in 35... Cisplatin | 18 Years - | Trans Tasman Radiation Oncology Group | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | NCT04301011 | Solid Tumor Microsatellite ... HPV Positive Or... Cervical Cancer Melanoma (Skin) Cutaneous Squam... Mesothelioma Renal Cell Carc... Oropharynx Canc... | TBio-6517 Pembrolizumab | 18 Years - | Turnstone Biologics, Corp. | |
| Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma | NCT01855451 | HPV Positive Or... | Cetuximab RT (70 Gy in 35... Cisplatin | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | NCT04129320 | Head and Neck C... Squamous Cell C... | enoblituzumab MGA012 MGD013 | 18 Years - | MacroGenics | |
| Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC | NCT03646461 | Head and Neck C... Squamous Cell C... | Ibrutinib 560mg... Cetuximab Nivolumab | 18 Years - | University of California, San Diego | |
| Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | NCT03611205 | Oropharyngeal S... HPV Positive Or... | Computed Tomogr... Positron Emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
